Skip to main content
Top
Published in: Calcified Tissue International 5/2011

01-11-2011 | Original Research

In Vitro Generation of Mature Human Osteoclasts

Authors: F. Hemingway, X. Cheng, H. J. Knowles, F. Martinez Estrada, S. Gordon, N. A. Athanasou

Published in: Calcified Tissue International | Issue 5/2011

Login to get access

Abstract

Mononuclear precursors of human osteoclasts are found in the CD14+ monocyte fraction of circulating peripheral blood mononuclear cells (PBMCs). It is possible to generate osteoclasts in vitro from PBMCs cultured with macrophage colony-stimulating factor and receptor activator for nuclear factor κB ligand. In these cultures, however, it is not possible to distinguish the effect of a specific agent on osteoclast resorption activity as opposed to osteoclast differentiation. To produce a population of mature human osteoclasts to study osteoclast lacunar resorption specifically, we cultured CD14+ human monocytes on hydrophobic dishes in order to generate and maintain osteoclasts in suspension prior to culturing them on coverslips and dentine slices. Multinucleated cells formed in these cultures expressed vitronectin receptor, tartrate-resistant acid phosphatase, and cathepsin K. These cells also produced F-actin rings and were capable of extensive lacunar resorption on dentine slices after 24 h in culture. Lacunar resorption was inhibited by calcitonin and zoledronate but not by osteoprotegerin. This method of generating a highly enriched population of mature human osteoclasts should provide a valuable means of specifically assessing the effect of molecular factors (e.g., cytokines, growth factors, hormones) and therapeutic agents on osteoclast resorption activity.
Literature
1.
go back to reference Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058–4060PubMedCrossRef Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058–4060PubMedCrossRef
2.
go back to reference Quinn JM, Sabokbar A, Athanasou NA (1996) Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells. J Pathol 179:106–111PubMedCrossRef Quinn JM, Sabokbar A, Athanasou NA (1996) Cells of the mononuclear phagocyte series differentiate into osteoclastic lacunar bone resorbing cells. J Pathol 179:106–111PubMedCrossRef
4.
go back to reference Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424–4427PubMedCrossRef Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424–4427PubMedCrossRef
5.
go back to reference Chambers TJ, Fuller K, McSheehy PM, Pringle JA (1985) The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 145:297–305PubMedCrossRef Chambers TJ, Fuller K, McSheehy PM, Pringle JA (1985) The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 145:297–305PubMedCrossRef
6.
go back to reference Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N (2005) Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 36:945–954PubMedCrossRef Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N (2005) Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 36:945–954PubMedCrossRef
7.
go back to reference Chambers TJ, Revell PA, Fuller K, Athanasou NA (1984) Resorption of bone by isolated rabbit osteoclasts. J Cell Sci 66:383–399PubMed Chambers TJ, Revell PA, Fuller K, Athanasou NA (1984) Resorption of bone by isolated rabbit osteoclasts. J Cell Sci 66:383–399PubMed
8.
go back to reference Oursler MJ, Collin-Osdoby P, Anderson F, Li L, Webber D, Osdoby P (1991) Isolation of avian osteoclasts: improved techniques to preferentially purify viable cells. J Bone Miner Res 6:375–385PubMedCrossRef Oursler MJ, Collin-Osdoby P, Anderson F, Li L, Webber D, Osdoby P (1991) Isolation of avian osteoclasts: improved techniques to preferentially purify viable cells. J Bone Miner Res 6:375–385PubMedCrossRef
9.
go back to reference Osdoby P, Kruhowshi M, Collin-Osdoby P (1992) Experimental systems for studying osteoclast biology. In: Rifkin B, Gay C (eds) Biology and physiology of the osteoclast. CRC Press, New York, pp 1–32 Osdoby P, Kruhowshi M, Collin-Osdoby P (1992) Experimental systems for studying osteoclast biology. In: Rifkin B, Gay C (eds) Biology and physiology of the osteoclast. CRC Press, New York, pp 1–32
10.
go back to reference Murrills RJ, Shane E, Lindsay R, Dempster DW (1989) Bone resorption by isolated human osteoclasts in vitro: effects of calcitonin. J Bone Miner Res 4:259–268PubMedCrossRef Murrills RJ, Shane E, Lindsay R, Dempster DW (1989) Bone resorption by isolated human osteoclasts in vitro: effects of calcitonin. J Bone Miner Res 4:259–268PubMedCrossRef
11.
go back to reference Chambers TJ, Dunn CJ (1983) Pharmacological control of osteoclastic motility. Calcif Tissue Int 35:566–570PubMedCrossRef Chambers TJ, Dunn CJ (1983) Pharmacological control of osteoclastic motility. Calcif Tissue Int 35:566–570PubMedCrossRef
12.
go back to reference McSheehy PM, Chambers TJ (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118:824–828PubMedCrossRef McSheehy PM, Chambers TJ (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118:824–828PubMedCrossRef
13.
go back to reference McSheehy PM, Chambers TJ (1987) 1,25-Dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption. J Clin Invest 80:425–429PubMedCrossRef McSheehy PM, Chambers TJ (1987) 1,25-Dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption. J Clin Invest 80:425–429PubMedCrossRef
14.
go back to reference Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285–290PubMedCrossRef Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34:285–290PubMedCrossRef
15.
go back to reference Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, Bilbe G (1997) Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20:81–86PubMedCrossRef Littlewood-Evans A, Kokubo T, Ishibashi O, Inaoka T, Wlodarski B, Gallagher JA, Bilbe G (1997) Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20:81–86PubMedCrossRef
16.
go back to reference Horton MA, Lewis D, McNulty K, Pringle JA, Chambers TJ (1985) Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res 45:5663–5669PubMed Horton MA, Lewis D, McNulty K, Pringle JA, Chambers TJ (1985) Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res 45:5663–5669PubMed
17.
go back to reference Yoshida S, Domon T, Wakita M (1989) Studies of the clear zone of osteoclasts: immunohistological aspects of its form and distribution. Arch Histol Cytol 52:513–520PubMedCrossRef Yoshida S, Domon T, Wakita M (1989) Studies of the clear zone of osteoclasts: immunohistological aspects of its form and distribution. Arch Histol Cytol 52:513–520PubMedCrossRef
18.
go back to reference Chambers TJ (1979) Phagocytosis and trypsin-resistant glass adhesion by osteoclasts in culture. J Pathol 127:55–60PubMedCrossRef Chambers TJ (1979) Phagocytosis and trypsin-resistant glass adhesion by osteoclasts in culture. J Pathol 127:55–60PubMedCrossRef
19.
go back to reference Chambers TJ, Magnus CJ (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27–39PubMedCrossRef Chambers TJ, Magnus CJ (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27–39PubMedCrossRef
20.
go back to reference Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167–171PubMedCrossRef Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167–171PubMedCrossRef
21.
go back to reference Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478–3484PubMedCrossRef Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141:3478–3484PubMedCrossRef
22.
go back to reference Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852–858PubMedCrossRef Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 18:852–858PubMedCrossRef
23.
go back to reference Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419–1427PubMedCrossRef Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT (2002) Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161:1419–1427PubMedCrossRef
24.
go back to reference Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, Miyata T, Kumegawa M (1998) Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 251:796–801PubMedCrossRef Hakeda Y, Kobayashi Y, Yamaguchi K, Yasuda H, Tsuda E, Higashio K, Miyata T, Kumegawa M (1998) Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem Biophys Res Commun 251:796–801PubMedCrossRef
25.
go back to reference Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370–377PubMedCrossRef Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM (2001) Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone 28:370–377PubMedCrossRef
26.
go back to reference Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538PubMedCrossRef Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527–538PubMedCrossRef
27.
go back to reference Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978PubMedCrossRef Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978PubMedCrossRef
28.
go back to reference Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033PubMedCrossRef Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033PubMedCrossRef
29.
go back to reference Kirstein B, Grabowska U, Samuelsson B, Shiroo M, Chambers TJ, Fuller K (2006) A novel assay for analysis of the regulation of the function of human osteoclasts. J Transl Med 4:45PubMedCrossRef Kirstein B, Grabowska U, Samuelsson B, Shiroo M, Chambers TJ, Fuller K (2006) A novel assay for analysis of the regulation of the function of human osteoclasts. J Transl Med 4:45PubMedCrossRef
30.
go back to reference Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R (2004) Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2:6PubMedCrossRef Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R (2004) Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2:6PubMedCrossRef
31.
go back to reference Fuller K, Ross JL, Szewczyk KA, Moss R, Chambers TJ (2010) Bone is not essential for osteoclast activation. PLoS One 5(9) Fuller K, Ross JL, Szewczyk KA, Moss R, Chambers TJ (2010) Bone is not essential for osteoclast activation. PLoS One 5(9)
Metadata
Title
In Vitro Generation of Mature Human Osteoclasts
Authors
F. Hemingway
X. Cheng
H. J. Knowles
F. Martinez Estrada
S. Gordon
N. A. Athanasou
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 5/2011
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-011-9530-0

Other articles of this Issue 5/2011

Calcified Tissue International 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.